Osteoprotegerin is a Significant Prognostic Factor for Overall Survival in Patients with Primary Systemic Amyloidosis Independent of the Mayo Staging

Efstathios Kastritis; M. Gavriatopoulos; Meletios A Dimopoulos; Evangelos Eleutherakis‐Papaiakovou; Nikolaos Kanellias; Μαρία Ρούσσου; Constandinos Pamboucas; Savvas Toumanidis; Evangelos Terpos

doi:10.1016/j.clml.2015.07.483

Back

Shared by

Meletios A Dimopoulos

Osteoprotegerin is a Significant Prognostic Factor for Overall Survival in Patients with Primary Systemic Amyloidosis Independent of the Mayo Staging

Article 2015 en

Authors

EK
Efstathios Kastritis
MG
M. Gavriatopoulos
Meletios A Dimopoulos

Related publications

Article2015

Osteoprotegerin is a significant prognostic factor for overall survival in patients with primary systemic amyloidosis independent of the Mayo staging

Efstathios Kastritis, Maria Gavriatopoulou, Meletios A Dimopoulos, Evangelos Eleutherakis‐Papaiakovou, Nikolaos Kanellias, Μαρία Ρούσσου, Constandinos Pamboucas, Savvas Toumanidis, Evangelos Terpos

Article2014

High Bone Turnover Is Present in Patients with Primary Systemic (AL) Amyloidosis and Increased Osteoprotegerin Identifies Patients with Poor Survival within Mayo Stage 1 Disease

Efstathios Kastritis, Maria Gavriatopoulou, Evangelos Eleutherakis‐Papaiakovou, Nikolaos Kanellias, Μαρία Ρούσσου, Constantinos Pamboucas, Savvas Toumanidis, Evangelos Terpos, Meletios A Dimopoulos

Editorial Material2019

Objective Response by mRECIST Is an Independent Prognostic Factor of Overall Survival in Systemic Therapy for Hepatocellular Carcinoma

Masatoshi Kudo

Article2008

Significant Activity of Bortezomib-Based Therapy in Patients with Primary Systemic (AL) Amyloidosis

Efstathios Kastritis, Ashutosh Wechalekar, Meletios A Dimopoulos, Giampaolo Merlini, Philip N. Hawkins, Vittorio Perfetti, Julian D. Gillmore, Giovanni Palladini

Preprint2019

Objective Response by mRECIST is an Independent Prognostic Factor for overall Survival in Hepatocellular Carcinoma in SILIUS Trial

Masatoshi Kudo, Kazuomi Ueshima, Yasutaka Chiba, Sadahisa Ogasawara, Shuntaro Obi, Namiki Izumi, Hiroshi Aikata, Hiroaki Nagano, Etsuro Hatano, Yutaka Sasaki, Keisuke Hino, Takashi Kumada, Kazuhide Yamamoto, Yasuharu Imai, Shouta Iwadou, Chikara Ogawa, Takuji Okusaka, Fumihiko Kanai, Yasuaki Arai

Osteoprotegerin is a Significant Prognostic Factor for Overall Survival in Patients with Primary Systemic Amyloidosis Independent of the Mayo Staging

Discussion(0)

Related publications

Osteoprotegerin is a significant prognostic factor for overall survival in patients with primary systemic amyloidosis independent of the Mayo staging

High Bone Turnover Is Present in Patients with Primary Systemic (AL) Amyloidosis and Increased Osteoprotegerin Identifies Patients with Poor Survival within Mayo Stage 1 Disease

Objective Response by mRECIST Is an Independent Prognostic Factor of Overall Survival in Systemic Therapy for Hepatocellular Carcinoma

Significant Activity of Bortezomib-Based Therapy in Patients with Primary Systemic (AL) Amyloidosis

Objective Response by mRECIST is an Independent Prognostic Factor for overall Survival in Hepatocellular Carcinoma in SILIUS Trial